Our MErCuRIC partners at the University of Torino (UNITO) have recently published two important papers. One appears in the October 5, 2017, edition of Gut, “Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.” The second paper titled, “Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor” was published in the October 2017 edition of Annals of Oncology. For additional information on these and other MErCuRIC publications, click here.
The team of Prof. Alberto Bardelli in the Department of Oncology at UNITO are pioneers in the tailoring of drug combinations to overcome resistance. During MErCuRIC, the group contribute to translational research aspects of the project and provide expertise in identifying resistance biomarkers, ctDNA based biopsies and xenopatient-based drug testing.